MedTrace Logo

A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma

NCT05022927 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 179

Last updated 2024-09-05

No results posted yet for this study

Summary

This is a multicenter, open-label, dose-escalation study designed to determine the maximum tolerated dose (MTD) by evaluating dose-limiting toxicities (DLTs) and to evaluate the safety, tolerability, pharmacokinetics, anti-tumor effect, and biomarkers of ERY974 in combination with atezolizumab and bevacizumab following premedication with tocilizumab in patients with locally advanced or metastatic HCC.

Conditions

  • Hepatocellular Carcinoma (HCC)

Interventions

DRUG

ERY974

ERY974 vial

DRUG

Tocilicumab

Tocilizumab vial

DRUG

Atezolizumab

Atezolizumab vial

DRUG

Bevacizumab

Bevacizumab vial

Sponsors & Collaborators

  • Chugai Pharmaceutical

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Japan
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05022927 on ClinicalTrials.gov